Table 3.
Univariate and multivariate analyses of risk factors for the MVI of cHCC-CCA
| Risk factor | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | |
| AFP ≥ 400, ng/mL | 3.065 (1.163, 8.075) | 0.023* | 3.163 (0.944, 10.603) | 0.062 |
| LMR | 2.109 (0.923, 4.82) | 0.077 | ||
| AAPR | 5.22 (1.077, 25.297) | 0.040* | 8.586 (1.226, 60.138) | 0.030* |
| APRI | 0.169 (0.035, 0.808) | 0.026* | ||
| ANRI | 0.267 (0.09, 0.791) | 0.017* | 0.237 (0.061, 0.915) | 0.037* |
| AGLR | 0.502 (0.234, 1.074) | 0.076 | ||
| NRPI | 3.109 (1.031, 9.369) | 0.044* | ||
| GAR | 0.525 (0.253, 1.088) | 0.083 | ||
| Non-smooth margin | 2.55 (1.214, 5.358) | 0.013* | 2.742 (1.032, 7.284) | 0.043* |
| Target sign on DWI | 0.455 (0.203, 1.018) | 0.055 | ||
| Arterial phase peritumoral enhancement | 8.256 (3.611, 18.877) | < 0.001* | 6.167 (2.457, 15.477) | < 0.001* |
CI confidence interval, AFP α-fetoprotein, LMR lymphocyte to monocyte ratio, AAPR albumin-to-alkaline phosphatase ratio, APRI aspartate aminotransferase-to-platelet ratio index, ANRI aspartate aminotransferase-to-neutrophil ratio index, AGLR (alkaline phosphatase + γ-glutamyltranspeptidase)-to-lymphocyte ratio, NRPI neutrophil-to-prealbumin ratio index, GAR γ-glutamyltranspeptidase-to-albumin ratio
*Indicate statistical significance